Phase II study of the c-SRC inhibitor AZD0530 after four cycles of cytoreductive chemotherapy for patients with extensive stage small cell lung carcinoma.

Trial Profile

Phase II study of the c-SRC inhibitor AZD0530 after four cycles of cytoreductive chemotherapy for patients with extensive stage small cell lung carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2014

At a glance

  • Drugs Saracatinib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jun 2012 Actual end date Nov 2008 added as reported by ClinicalTrials.gov.
    • 18 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Sep 2008 Basic check conducted, last updated 9-09-2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top